Skip to content

A Study on the Inheritance of Yan Xiaoping's Experience in Treating Ankylosing Spondylitis Based on Qualitative Research(RCT)

A Study on the Inheritance of Yan Xiaoping's Experience in Treating Ankylosing Spondylitis Based on Qualitative Research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001959
Enrollment
Unknown
Registered
2025-10-22
Start date
2025-10-24
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ankylosing spondylitis

Interventions

The Treatment Arm Combining the New "Cold-Heat Syndrome Differentiation" Protocol with Conventional Western Therapy:The New "Cold-Heat Syndrome Differentiation" Protocol (Oral & Topical) combined Con
other traditional Chinese medicine treatment with Conventional Western Therapy:other traditional Chinese medicine treatment(Oral & Topical) combined Conventional Western Therapy

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)Age 16-75 years; 2)Meet diagnostic criteria for active Ankylosing Spondylitis;3) Meet diagnostic criteria of the Chinese Medicine "Hunchback Pattern" Syndrome Scale;4) Voluntarily sign informed consent forms;5) Patients regularly using disease-modifying antirheumatic drugs (DMARDs) such as Sulfasalazine (SASP) Methotrexate (MTX) or Leflunomide (LEF) are eligible if maintained on stable doses for =12 weeks before enrollment with unchanged doses during the 12-week study period;6) Patients regularly using biologics or small-molecule targeted drugs are eligible if maintained on stable doses for =12 weeks before enrollment with unchanged doses during the 12-week study period.

Exclusion criteria

Exclusion criteria: 1)Patients not meeting the above inclusion criteria; 2) Pregnant or lactating women individuals with psychiatric disorders severe malnutrition or major impairment in cardiac cerebral renal or hematopoietic systems; 3) Patients with concurrent seronegative spondyloarthropathies or other coexisting rheumatic diseases.1)

Design outcomes

Primary

MeasureTime frame
Assessment of SpondyloArthritis 20% response criterion;

Secondary

MeasureTime frame
Assessment of SpondyloArthritis 40% response criterion;ankylosing spondylitis quality of life;the MOS item short from health survey;Traditional Chinese Medicine Syndrome Scoring;Bath Ankylosing Spondylitis Measurement Index;the Bath Ankylosing Spondylitis Disease Activity Index;Bath Ankylosing Spondy litis Patient Global Score;Bath Ankylosing Spondylitis Fundation Index;spine pain;Morning stiffness;Night pain VAS score;C-reactive protein;erythrocyte sedimentation Rate;Doctor's overall evaluation VAS score;

Countries

China

Contacts

Public ContactWeiping Kong

China-Japan Friendship Hospital

kongweiping75@126.com13611038252

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026